Finally, the potential role of emerging pharmacologic therapies, particularly GLP-1 receptor agonists, warrants investigation with regard to their impact on conservative obesity treatment strategies and surgical decision-making. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.